Macao to Buy 400,000 Fosun-BioNTech mRNA Covid-19 Vaccines
Zhang Yushuo
DATE:  Feb 26 2021
/ SOURCE:  Yicai
Macao to Buy 400,000 Fosun-BioNTech mRNA Covid-19 Vaccines Macao to Buy 400,000 Fosun-BioNTech mRNA Covid-19 Vaccines

(Yicai Global) Feb. 26 -- China’s Macao Special Administrative Region has followed Hong Kong's lead by allowing imports of a Covid-19 vaccine based on German BioNTech's mRNA platform.

Macao's government plans to buy 400,000 doses for the region's immunization program after granting the special import permit, Fosun Pharmaceutical Group and BioNTech said in a statement yesterday. The first order will not exceed 105,000 doses. Fosun, which is testing the inoculation in China, has the German firm's approval to commercialize the product in China.

The Macao deal shouldn't majorly affect Fosun's business performance, it added. The Shanghai-based firm inked a deal with BioNTech in March 2020 for the exclusive rights to develop and market the Mainz-based biotech company’s Covid-19 vaccines in China.

The Hong Kong SAR chose the mRNA vaccine, named BNT162b2, as the city's first approved Covid-19 vaccine under an Emergency Use Authorization last month. US drug giant Pfizer, another partner of BioNTech, has already been selling BNT162b2 in over 50 countries, including the UK, US, and Canada. But the product is still undergoing phase II trials in China's mainland.

Before this, Macao has permitted the use of an inactivated Covid-19 vaccine made by China National Pharmaceutical Group, also known as Sinopharm.

Editor: Emmi Laine, Xiao Yi

Follow Yicai Global on
Keywords:   Forsun,BioNTech,mRNA,Macao,pfizer